Material Requirements to Support Gene Therapy Development

Plasmid DNA products are one of the most common non-viral vectors, frequently used in both in vivo and ex vivo gene therapies. As a result, they can be utilised as drug substance (DS)/drug product (DP), intermediate or starting material.

COVID-19 represents a global crisis, yet significant knowledge gaps remain about human immunity to SARS-CoV-2. As many researchers raced to develop the vaccines and therapeutics needed to mitigate the pandemic, other investigators took up the task of understanding the human body’s diverse response to this virus. With technology advancing exponentially, researchers have an arsenal of analytic tools now at their disposal to decipher the most elusive aspects of viral immunobiology.

T cells play a critical role in the adaptive immune response. In naive T cells, binding of the T-cell receptor (TCR) to peptides complexed with major histocompatibility complex triggers an intricate signaling mechanism leading to T-cell activation, proliferation, and production of cytokines. Modulating the TCR signaling pathway using biologics, small molecules, or genetic engineering is highly relevant to many therapeutic areas, including cancer immunotherapy, adoptive cell therapy, vaccine development, and autoimmune disease.

From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in research due to their role as intercellular messengers in health and disease. While their translational applications appear unlimited, the study of exosomes is challenged by their small size and heterogenous nature. In this webinar you will learn more about the common methods for exosome research and the proficient tools that Miltenyi Biotec offers to isolate and analyze exosomes. Join to connect with us and hear more.